Welcome to our dedicated page for Inspira Technologies Oxy Bhn news (Ticker: IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy Bhn stock.
Inspira Technologies Oxy BHN Ltd (IINN) delivers innovative respiratory care solutions through its non-invasive INSPIRA ART system and HYLA blood monitoring technology. This page provides investors and healthcare professionals with essential updates on regulatory milestones, product developments, and clinical partnerships shaping the future of critical care.
Access real-time information on FDA clearances, technology evaluations, and strategic collaborations. Our curated news ensures you stay informed about advancements in extracorporeal oxygenation and AI-driven blood analytics without speculative commentary.
Discover updates across key categories including regulatory submissions, clinical trial results, product launches, and global distribution agreements. All content is verified for accuracy and relevance to support informed decision-making.
Bookmark this page for streamlined access to Inspira Technologies' progress in redefining respiratory support systems. Check back regularly for authoritative reporting on innovations addressing acute respiratory failure and ICU resource challenges.
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN)(NASDAQ:IINNW) is set to present at the 2023 Planet MicroCap Showcase in Las Vegas on April 26, 2023, at 14:30 CST. Joe Hayon, President and Co-Founder, will lead the presentation. Interested parties can access the live presentation via the provided webcast link. Registration for the event is necessary, which can be done here. Additionally, one-on-one virtual meetings can be scheduled with Joe throughout May by using this link. Inspira Technologies focuses on innovative respiratory treatments, particularly its Augmented Respiration Technology, aimed at improving patient outcomes while minimizing the use of invasive mechanical ventilation.
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) reported its financial results for the year ended December 31, 2022. The company has $13.9 million in cash, a decrease from $23.7 million in 2021, with shareholders' equity falling to $12.8 million from $20.3 million. R&D expenses increased to $8 million from $3.9 million in the previous year. The net loss showed improvement at $10.3 million compared to $17 million in 2021. The company plans to submit its ALICE device for FDA approval in H2 2023 and is conducting clinical studies for its HYLA blood sensor. Inspira continues to advance its INSPIRA ART system aimed at non-invasive respiratory treatment.
Inspira Technologies has announced the first-in-human use of its HYLA Blood sensor during open-heart surgery at Sheba Medical Center in Israel. This non-invasive sensor utilizes machine learning to measure key blood parameters in real-time, aiming to enhance patient care during procedures like VV-ECMO and VA-ECMO. The ongoing HYLA clinical study compares the sensor's performance against traditional blood gas analyzers. The company's advanced Augmented Respiration Technology (INSPIRA ART) seeks to improve oxygen saturation levels without invasive ventilation methods. Regulatory approval is still pending for these technologies.
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) has received Ethics Committee approval from
Inspira Technologies has received a patent from the U.S. Patent and Trademark Office for its innovative convertible dual lumen cannula device, crucial for its INSPIRA ART System. The patent encompasses 20 claims deemed novel, emphasizing its inventive step and industrial applicability. The device allows intravascular conversion of a single-lumen cannula into a dual lumen one, enhancing usability during medical procedures like ECMO. The company plans to seek international patents, integrate this device with existing products, and consider its separate commercialization as a disposable item, aiming to improve patient safety and procedural efficiency.
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) has signed an exclusive OEM agreement with Terumo Cardiovascular, enhancing its product development in respiratory support technology. This partnership allows Terumo to manufacture a flow mechanism for Inspira's innovative INSPIRA ART system, designed to improve oxygen saturation in patients while they remain awake. The agreement aligns with Inspira's strategy to collaborate with major medical device companies to bring its technology to market, although the products have yet to be tested in humans.
Inspira Technologies (Nasdaq: IINN) will be featured in an interview on The RedChip Money Report® airing on Bloomberg TV on December 24, 2022, at 7 p.m. ET. Co-Founder Joe Hayon will discuss their innovative respiratory technology aimed at reducing the need for invasive mechanical ventilation. The company plans to initiate human studies at leading medical centers. Inspira's technology, known as Augmented Respiration Technology (INSPIRA ART), is designed to help patients maintain oxygen levels while minimizing the risks associated with traditional ventilation methods.
Inspira Technologies will be featured on The RedChip Money Report on Bloomberg TV on December 24, 2022. Co-Founder Joe Hayon discusses Inspira's innovative respiratory support technology aimed at reducing reliance on invasive mechanical ventilation. The interview highlights plans to initiate human studies and the potential of Inspira's technology to become the new standard of care for acute respiratory failure. The company's products are still in development and have not been tested on humans.